Product Reports Resources Pricing Login Book a demo

Acerta Pharma

Biotech & Life Sciences · Oss, Netherlands · Founded 2013

Clinical research on cancer and autoimmune diseases

Valuation $5–10B
Revenue $1–5B
Headcount 100–500
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Acerta Pharma and the history behind them.
Power Law Unicorn$1–10B valuation tier Thoroughbred$100M+ revenue

Talent graph

Acerta Pharma's talent

Book a demo to see the people
Employees mapped 141 incl. 3 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 7 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia 4 alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

3 investors on Acerta Pharma's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 1 investor entered at this stage
BioGeneration Ventures
Series A 2 investors entered at this stage
OrbiMed
Frazier Healthcare Partners

Acerta Pharma mafia

Startups founded by Acerta Pharma alumni

Former Acerta Pharma employees who went on to start their own companies. Sorted by Dealroom signal score.

AzafarosEst. 2018
EWEdward Van WezelNetherlands
Signal score92
Artica TherapeuticsEst. 2020
Tjeerd BarfNetherlands
Signal score83
AirNexis TherapeuticsEst. 2025
Maria FardisUnited States
Signal score56
VelosBioEst. 2017
Dave JohnsonUnited States
Signal score56

Book a demo to explore the full alumni network →

Global footprint

Where Acerta Pharma has talent and traffic

Workforce by country
11 countries with
team presence
🇳🇱 Netherlands78%
🇺🇸 United States9.5%
🇬🇧 United Kingdom2.9%
🇩🇪 Germany2.7%
🇫🇷 France1.7%
Top 5 of 11 shown
Web traffic by country
900 monthly visits
across markets
🇺🇸 United States66.7%
🇮🇳 India22.2%
🇳🇱 Netherlands11.1%
Top 3 markets shown

Patent intelligence

$41M patent portfolio · 26 active families

Estimated portfolio value
$41M
0.58% of valuation · 3.7× smaller than top peer Pharmacyclics ($150M)
26 active patent families
Where Acerta Pharma innovates Btk inhibitorsCancer researchCarcinosisDiseaseImidazole

Where Acerta Pharma concentrates vs peers

Each axis is a top-10 topic across Acerta Pharma and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Acerta Pharma

An AI-synthesized read of the highest-engagement posts about Acerta Pharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Acerta Pharma on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles